click enter text
macro drug polici hit anoth hardwar
tug war continu water result drove third down-revis
year guidanc yet stock trade near pariti price-to-earnings tool
investor increasingli focus leverag given view
share buy-back take float
year drive ep multipl unsustain way
buy-back could remain materi vs includ
buy-back see downsid consensu enter week impli
oper expens growth acceler guidanc rais anoth
concern ep growth sustain cut ep growth estim
view revenue/margin challeng like persist
flag quarter ago buy-back easi comp
risk tactic neg structur believ share
overvalu remain under-perform pt focu share
risk hardwar exposur cyclic break trend
model exhibit report
pharma hardwar wat result commentari
concentr weaker hardwar trend septemb quarter-end
hardwar delay pharma us drove weakest pharma/wat
quarter sinc gener litig drug price focu point line
dilig trend exhibit direct consist
tmo/dhr comment instrument small molecul demand
lower estim preview account risk trend
pharma macro categori industri govern spend trend
remain weak tie macro polici pars risk number
tool peer challeng higher hardwar mix
cyclicality/pharma mix mtd/agilent/pki china like improv
agil given diagnost purchas uncertainti ahead
guidanc model updat guidanc sale cut
impli total sale flat ex-fx benefit extra
sell day guidanc ep growth consensu model
ep model revis modest concentr
top line gross margin name cut nomin revenu
cut gross margin exhibit
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
exhibit annual quarterli guidanc
exhibit top-lin organ growth slow tougher macro
gener drug manufactur
page
biopharma org yoy growthorg organ growthyoy growthstackedforecastannualguid growth margin fx fx fx sale comp tax fx impact fx impact research
page
mncon prior yearorgan chang bp ta org sell day gross oper incom interest incom incom net incom share gross bp oper bpseffect tax bpsnet bp organ gross gross opex growth ex shift itemspharma non price-to-earnings premium tool median median median
page
yieldfcf compound-annual-growth-rate ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool ntm price-to-earnings ratio median price-to-earnings premium compound-annual-growth-rate corp
note ex-bioacc/synapt/cycl refer division organ growth without assum impact new product announc
page
estimate day ex day ex growth categori categori
note figur million unless state per-shar term
page
note figur million unless state per-shar term
page
